IN THE CLAIMS (37 CFR 1.121 Revised)

1. (previously and currently amended) A pharmaceutical composition which comprises:

an essentially nonaqueous, filterable liquid concentrate solution of sertraline hydrochloride for oral administration comprising about ~~[15]~~ 18 mg/ml to about ~~[30]~~ 78 mg/ml of sertraline hydrochloride and pharmaceutically acceptable excipients; wherein the excipients are ethanol and glycerin in an amount of about 8 to about ~~[20%]~~ 50% ethanol ~~[(]~~by weight~~[)]~~ in glycerin.

Claims 2 - 6 (previously canceled)

7. (currently amended) The composition of claim ~~[6]~~ 1 wherein the concentrate further comprises one or more flavoring agents and one or more pharmaceutically acceptable preservatives.

8. (previously amended) The composition of claim 7 wherein the flavoring agents are selected from the group consisting of peppermint, spearmint and menthol; and wherein the preservatives are selected from the group consisting of butylhydroxytoluene, butylated hydroxyanisole, propyl gallate, ascorbic acid, ascorbyl palmitate, sodium metabisulfite, sodium bisulfite, sodium thiosulfate, sodium hydroxide, cysteine, ethylenediamine tetraacetic acid or salts thereof, citric acid, triethanolamine, thioglycerol, methylparaben and propylparaben.

9. (original) The composition of claim 8 wherein the flavoring agent is menthol and wherein the preservative is butylhydroxytoluene.

10. (original) The composition of claim 9 wherein each ml of the concentrate comprises about 22.4 mg of sertraline hydrochloride, about 151 mg of ethanol, about 0.50 mg of menthol, about 0.10 mg of butylhydroxytoluene, and about 1011 mg of glycerin.

11. (canceled)

12. (previously amended) A method of using an essentially nonaqueous, liquid concentrate of sertraline hydrochloride of claim 1 to prepare an aqueous solution of sertraline which comprises diluting the concentrate in an aqueous diluent prior to oral administration.

13. (previously canceled)

14. (original) The method of claim 12 wherein the diluent is selected from the group consisting of water, orange juice, ginger ale, lemon-lime soda and lemonade.

15. (previously amended) A method of treating or preventing diseases or conditions which are caused by disorders of the serotonergic system which comprises:

a) diluting an essentially nonaqueous, liquid concentrate of sertraline hydrochloride of claim 1 in an aqueous diluent; and

b) orally administering the resulting aqueous solution to a patient in need thereof.

16. (original) The method of claim 15 wherein the diluent is selected from the group consisting of: water, orange juice, ginger ale, lemon-lime soda and lemonade.

17. (previously amended) A method of treating or preventing diseases or conditions selected from the group consisting of depression, anorexia, chemical dependencies, anxiety-related disorders, premature ejaculation, cancer and post myocardial infarction, which comprises:

a) diluting an essentially nonaqueous, liquid concentrate of sertraline hydrochloride of claim 1 in an aqueous diluent; and

b) orally administering the resulting aqueous solution to a patient in need thereof.

18. (original) The method of claim 17 wherein the anxiety-related disorders are selected from the group consisting of: panic disorder, obsessive-compulsive disorder, generalized anxiety disorder, phobias, post traumatic stress disorder and avoidant personality disorder.

19. (original) The method of claim 17 wherein the diluent is selected from the group consisting of: water, orange juice, ginger ale, lemon-lime soda and lemonade.

D3

20. (new) The pharmaceutical composition of claim 1 comprising about 18 mg/ml to about 30 mg/ml of sertraline hydrochloride and ethanol and glycerin in an amount of about 8 to about 20% ethanol by weight in glycerin.